Compare ARTNA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | CERS |
|---|---|---|
| Founded | 1905 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | EDP Services |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.1M | 276.0M |
| IPO Year | 1996 | 1997 |
| Metric | ARTNA | CERS |
|---|---|---|
| Price | $33.67 | $2.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 32.7K | ★ 1.1M |
| Earning Date | 03-24-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 12.02 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | $111,776,000.00 | ★ $199,191,000.00 |
| Revenue This Year | $7.82 | $25.31 |
| Revenue Next Year | $3.54 | $9.50 |
| P/E Ratio | $15.45 | ★ N/A |
| Revenue Growth | 5.80 | ★ 13.03 |
| 52 Week Low | $29.97 | $1.12 |
| 52 Week High | $36.19 | $2.96 |
| Indicator | ARTNA | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 48.74 |
| Support Level | $32.56 | $2.05 |
| Resistance Level | $33.49 | $2.26 |
| Average True Range (ATR) | 0.70 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 98.84 | 39.39 |
Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.